| Gene symbol | TTR | Synonyms | ATTR, CTS, CTS1, HEL111, HsT2651, PALB, TBPA, TTN | Type of gene | protein-coding |
| Chromosome | 18 | Map location | 18q12.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | transthyretin | ||||
| GTO ID | GTC3705 |
| Trial ID | NCT06194825 |
| Disease | Transthyretin Amyloid Cardiomyopathy |
| Altered gene | TTR |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | AKCEA-TTR-LRx|Eplontersen|ION-682884|IONIS-TTR-LRx|ION-682884|Wainua |
| Location approved | US |
| Phase | Phase3 |
| Recruitment status | Recruiting |
| Title | A Phase 3, Randomized Study, With Initial 24-week, Double-Blind and Placebo-Controlled Treatment Phase, Followed by An 80-week Open-label Extension Treatment Phase to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-Term Safety in Chinese Participants With Transthyretin Amyloid Cardiomyopathy (EPIC-ATTR) |
| Year | 2023 |
| Country | China |
| Company sponsor | AstraZeneca |
| Other ID(s) | D8450C00005 |
| Vector information | |||
|
|||
| Cohort1: Eplontersen | |||||||||
|
|||||||||
| Cohort2: Placebo | |||||||||
|
|||||||||